Physician

David Tin Chu, M.D.

According to 2025 Medicare claims, David Chu, M.D. (NPI: 1750585287) practices hematology/oncology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Suffolk, NY. This provider's primary affiliated billing organization is NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (NPI: 1396794574; TIN: 112419534) and primary practice location at 11776-0001. Chu is affiliated with the ilumed, LLC (ACO ID: D0005) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Chu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,630 traditional Medicare patients, billed 241,337 HCPCS/CPT codes, and received $3,307,479 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 2,505 prescription claims across 377 beneficiaries totaling $8,456,965 in drug costs, led by Aranesp (Darbepoetin Alfa In Polysorbat). DME data shows 25 claims. Open Payments data shows 4 records totaling $574. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,655,224 and ending at $3,307,479. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,404,003 to $8,456,965. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,915	236,778	$2,655,224
2016	2,151	252,990	$2,656,817
2017	2,383	346,614	$4,356,235
2018	2,480	338,646	$4,282,145
2019	2,038	302,711	$3,191,758
2020	2,141	273,464	$3,770,036
2021	2,857	488,671	$5,669,963
2022	2,704	511,309	$6,126,695
2023	2,592	323,812	$4,326,665
2024	2,630	241,337	$3,307,479

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	246	1,351	$1,404,003
2016	260	1,571	$1,939,071
2017	280	1,667	$3,049,107
2018	280	1,697	$2,652,442
2019	305	1,747	$3,137,393
2020	309	1,870	$3,992,768
2021	366	2,124	$4,432,320
2022	360	2,230	$6,128,835
2023	364	2,273	$6,571,557
2024	377	2,505	$8,456,965

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	15	85	$55,396
2016	27	39	$22,871
2017	66	138	$36,393
2018	68	129	$18,700
2019	38	77	$7,602
2020	36	68	$5,522
2021	36	124	$8,212
2022	30	136	$5,064
2023	N/R	72	$10,264
2024	N/R	25	$711

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	1,815	3,556	$10
36415	Insertion of needle into vein for collection of blood sample	2,023	4,185	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,974	4,088	$8
83735	Magnesium level	1,596	3,179	$7
84100	Phosphate level	1,645	3,243	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Aranesp	Darbepoetin Alfa In Polysorbat	237	4,996	$708,611
Imbruvica	Ibrutinib	46	1,288	$707,410
Lenvima	Lenvatinib Mesylate	19	570	$458,185
Ibrance	Palbociclib	29	812	$450,106
Somatuline Depot	Lanreotide Acetate	40	1,132	$366,167

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$548
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$192	Intera Oncology, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$382	Daiichi Sankyo Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Tin Chu, M.D.?

Tedicare shows public-source Medicare data for David Tin Chu, M.D. (NPI 1750585287), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Tin Chu, M.D. have ACO affiliation data?

David Tin Chu, M.D. is shown with ACO affiliation data for ilumed, LLC (REACH, ACO ID D0005) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to David Tin Chu, M.D.?

David Tin Chu, M.D. is linked to NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (billing NPI 1396794574) in the available physician profile data.

Does David Tin Chu, M.D. have Open Payments data?

David Tin Chu, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.